Physician profile
Stephen E Stonehouse
NPI 1285904706
$2,836.73
in general payments reported to CMS, 2019-2025
24 companies · $19.31 in 2025
The $19.31 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $321 · 2021: $1,105 · 2022: $863 · 2023: $486 · 2024: $42.34 · 2025: $19.31.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $548.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $547.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $518.69 | 2020-2023 | Jardiance |
| Novo Nordisk INC | $382.78 | 2020-2023 | Ozempic, Wegovy |
| Abbvie INC. | $311.04 | 2021-2024 | Vraylar, Synthroid, Qulipta |
| Bausch Health US, LLC | $281.80 | 2020-2022 | |
| Amarin Pharma, INC. | $210.20 | 2020-2022 | |
| Merck Sharp & Dohme LLC | $201.42 | 2020-2023 | Gardasil 9, Vaxneuvance, Pneumovax 23 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $126.27 | 2020-2023 | Cycloset |
| Amgen INC. | $106.85 | 2021-2025 | Repatha |
| Glaxosmithkline, LLC. | $94.66 | 2022-2023 | Shingrix, Arexvy, Trelegy Ellipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $76.15 | 2021-2023 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $74.80 | 2022 | |
| Exact Sciences Corporation | $71.97 | 2023 | Cologuard Collection Kit |
| Astrazeneca Pharmaceuticals Lp | $68.23 | 2021-2023 | Farxiga |
| Kowa Pharmaceuticals America, INC. | $60.70 | 2020-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $56.46 | 2021-2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $47.53 | 2021 | |
| Astellas Pharma US INC | $27.18 | 2023 | Veozah |
| Impel Pharmaceuticals INC. | $21.29 | 2022 | |
| Dermira, INC. | $18.20 | 2020 | |
| Novartis Pharmaceuticals Corporation | $18.09 | 2023 | |
| Teva Pharmaceuticals USA, INC. | $18.07 | 2021 | |
| Endo Pharmaceuticals INC. | $17.68 | 2021 | |
| Vistapharm, INC. | $13.37 | 2021 | |
| Phadia US INC. | $13.30 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Stonehouse listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.